China News Service, June 5 (Xinhua) reported that on the 4th local time, after doctors and scientists questioned the validity of the data, a research paper on the effectiveness of the drug hydroxychloroquine in the treatment of patients with new crowns, from "Liu Withdrawn from the Medical Journal of Leaf Cutter.
Data Map: US President Trump
The previous study concluded that patients taking the antimalarial drug hydroxychloroquine had a higher risk of death than those who did not, leading some researchers to discontinue clinical trials.
The three authors of the study were led by Mandip Mehra at Harvard Medical School and published in late May. But a few days ago, they withdrew the study from The Lancet because the independent peer reviewers did not have access to the data for analysis.
The author wrote in a statement on June 4: "We have all participated in this cooperation and sincerely contribute in the extraordinary period of the new crown pandemic." "For any embarrassment or inconvenience that may result from this, We apologize and apologize to you, the editor and the readers of the journal."
The report said that the study used data from more than 96,000 inpatients with new crowns in 671 hospitals on six continents by Surgisphere Corporation. However, the company told peer reviewers that it will not disclose the complete data set used for research because it would violate customer agreements and confidentiality requirements.
Surgisphere Corporation belongs to one of the study co-authors, Sapan Desai. The report said that Desai did not sign a withdrawal request with three other co-authors.
"The Lancet" wrote in a statement that it "very attaches importance to the issue of scientific integrity" and "there are many outstanding issues regarding the Surgisphere and the data allegedly included in this study."
Earlier, after a driver of President Trump tested the new crown positively, Trump underwent a two-week course of hydroxychloroquine treatment. But another study previously published showed that the drug cannot effectively prevent the new crown.
Another study of 368 patients published in the New England Journal of Medicine in April found that the two main outcomes of patients with new crowns treated with hydroxychloroquine were either death or critical illness and required the use of a ventilator.
Although not a rigorous trial, but including trials led by the National Institutes of Health and the World Health Organization, randomized trials of hydroxychloroquine are still in progress.